Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

ALVO

ALVO News

Newswire

13:22

Alvotech Securities Investigation: Rosen Law Firm Encourages Investors to Inquire

20:06

Alvotech Reports 420% Revenue Growth in 2024, Guides 20% Growth in 2025 Amid Regulatory Challenges

05:55

Alvotech's AVT03 Receives European Commission Approval as Denosumab Biosimilar.

05:38

Alvotech's AVT03 Biosimilar Approved in Europe for Osteoporosis and Cancer Treatment.

05:31

Alvotech Receives EU Marketing Authorization for AVT03, a Biosimilar to Prolia and Xgeva

View More

About ALVO

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More